NRSN vs. INDP, VINC, NERV, VBIV, ORGS, AYTU, TLPH, APM, TRAW, and VAXX
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Indaptus Therapeutics (INDP), Vincerx Pharma (VINC), Minerva Neurosciences (NERV), VBI Vaccines (VBIV), Orgenesis (ORGS), Aytu BioPharma (AYTU), Talphera (TLPH), Aptorum Group (APM), Traws Pharma (TRAW), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical preparations" industry.
Indaptus Therapeutics (NASDAQ:INDP) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics' return on equity of -91.78% beat Indaptus Therapeutics' return on equity.
In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 4 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.07 beat Indaptus Therapeutics' score of 0.36 indicating that Indaptus Therapeutics is being referred to more favorably in the media.
Indaptus Therapeutics received 8 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 83.33% of users gave Indaptus Therapeutics an outperform vote.
7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 27.1% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Indaptus Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
Indaptus Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 474.16%. Given NeuroSense Therapeutics' higher possible upside, equities research analysts clearly believe Indaptus Therapeutics is more favorable than NeuroSense Therapeutics.
Summary
Indaptus Therapeutics beats NeuroSense Therapeutics on 7 of the 12 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
